Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news
DBT shows how advanced cancers develop from longer intervals
Advanced cancers on digital breast tomosynthesis (DBT) occur with longer intervals from prior screening, a study presented November 30 at the RSNA 2023 annual meeting found.In her talk, Liane Philpotts, MD, from Yale University presented her team’s findings showing through DBT screening that until about 21 months, the rate of advanced cancers was stable. After that time point, it increased by nearly 10%.“With DBT screening, an interval of less than two years may help reduce the rate of advanced cancers,” Philpotts said. While breast cancer screening aims to detect nonlethal cancers early, many women do not adhere to ...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Breast Imaging Source Type: news
Avoid Anti-HER2 Cancer Therapies During Pregnancy Avoid Anti-HER2 Cancer Therapies During Pregnancy
Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 29, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Neratinib, Fulvestrant, Trastuzumab Combo Aids Metastatic Breast Cancer
TUESDAY, Nov. 28, 2023 -- For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2023 Category: Pharmaceuticals Source Type: news
SABCS 2023: Anticipating New Data in HR+/HER2- Breast Cancer SABCS 2023: Anticipating New Data in HR+/HER2- Breast Cancer
Tarah J. Ballinger, MD, awaits new updates in HR+/HER2- breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
FDA Approves Truqap (capivasertib) plus Faslodex for Patients with Advanced HR-Positive Breast Cancer
17 November 2023 -- AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 17, 2023 Category: Drugs & Pharmacology Source Type: news
FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer
Adding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
First AKT Inhibitor Approved for Advanced Breast Cancer
(MedPage Today) -- The FDA approved the first-in-class AKT inhibitor capivasertib (Truqap), in combination with fulvestrant, for locally advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer and at least one specific genetic... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 17, 2023 Category: American Health Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval marks seventh gastrointestinal cancer indication for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
Communication Strategies in Breast Cancer (HER2+) Communication Strategies in Breast Cancer (HER2+)
A breast cancer specialist and a patient with HER2+ breast cancer share thoughts on improving communication regarding diagnosis of metastatic cancer, treatment considerations, and survivorship.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2023 Category: Consumer Health News Tags: None Care Cues Source Type: news
FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Improving Shared Decision-Making in HER2-Low Breast Cancer Improving Shared Decision-Making in HER2-Low Breast Cancer
A breast cancer specialist and a patient with metastatic HER2-low disease share perspectives on optimizing doctor-patient communication at key changes in treatment, such as starting hormonal therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2023 Category: Consumer Health News Tags: None Care Cues Source Type: news
Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer
THURSDAY, Nov. 16, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2023 Category: Pharmaceuticals Source Type: news
Highlights in Early Breast Cancer From ESMO 2023 Highlights in Early Breast Cancer From ESMO 2023
Highlights in early breast cancer from ESMO 2023 include 5-year results from KEYNOTE-522 in TNBC, pCR benefits in ER+/HER2-, and a genomic risk score in HER2+, as reported by Dr Lisa Carey.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
